<DOC>
	<DOC>NCT02174432</DOC>
	<brief_summary>The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.</brief_summary>
	<brief_title>Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis</brief_title>
	<detailed_description />
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject completed participation in the TR03 study Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study. Subject is a pregnant or lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Itch</keyword>
	<keyword>Chronic Itch</keyword>
	<keyword>Nalbupine</keyword>
</DOC>